Last Name First Name Roles Relationships Company Name
|
|
|
- Aubrey Fletcher
- 5 years ago
- Views:
Transcription
1 Speakers IGCS16 CME Disclo Last Name First Name Roles Relationships Company Name Honoraria/ Expenses Abu-Rustum Nadeem R. Scientific/Education Planning Committee Invited Speaker/Faculty Amant Frederic Scientific/Education Planning Committee Angioli Roberto Invited Speaker/Faculty Barakat Richard Board of Directors Bats Anne-Sophie Invited Speaker/Faculty Yes Benedetti Panici Pierluigi Poster/Oral Presenter Roche and Intuitive Surgical Berek Jonathan Invited Speaker/Faculty Yes Tesaro Bernardini Marcus Invited Speaker/Faculty Yes AstraZeneca Bhatla Neerja Invited Speaker/Faculty Bookman Michael Invited Speaker/Faculty Yes McKesson Specialty Health
2 Genentech AstraZeneca Clovis Endocyte
3 Immunogen Tesaro Botha Hennie Invited Speaker/Faculty Yes Boyd Jeff Invited Speaker/Faculty Buda Alessandro Invited Speaker/Faculty Chi Dennis Invited Speaker/Faculty Coleman Robert L Invited Speaker/Faculty Yes Poster/Oral Presenter Board of Directors GlaxoSmithKline Merck Abbott Laboratories Advaxis AstraZeneca Bayer
4 Genentech Janssen Pharmaceuticals Colombo Nicoletta Invited Speaker/Faculty Yes Correa Raimundo Invited Speaker/Faculty Poster/Oral Presenter Covens Allan Creutzberg Carien Invited Speaker/Faculty Denny Lynette Scientific/Education Planning Committee Yes Denschlag Dominik Invited Speaker/Faculty Yes Domingo Efren Invited Speaker/Faculty Dowdy Sean Scientific/Education Planning Committee Invited Speaker/Faculty Poster/Oral Presenter Committee (CME Research other) Roche Pharma Mar Amgen Merck Glaxo MSD Clovis AstraZeneca Merck GlaxoSmithKline Hoffmann-La Roche KLS Martin Serag-Wiesner
5 Farthing Alan Invited Speaker/Faculty Fotopoulou Christina Invited Speaker/Faculty Friedlander Michael Ganesan Prasanth Invited Speaker/Faculty Gerda Zahl Eriksson Ane Scientific/Education Planning Committee Gershenson David Invited Speaker/Faculty Yes Johnson&Johnson Biogen Idec celgene Pfizer
6 Elsevier UpToDate NCI US Clovis UT MD Anderson Cancer Center
7 Proctor&Gamble Gotlieb Walter Scientific/Education Planning Committee Yes Gwin Katja Invited Speaker/Faculty Hacker Neville Invited Speaker/Faculty Halaska Michael Invited Speaker/Faculty Harter Philipp Invited Speaker/Faculty Yes Kim Jae-Weon Scientific/Education Planning Committee Invited Speaker/Faculty Kimura Tadashi Invited Speaker/Faculty Yes Kumarasamy Suresh Invited Speaker/Faculty Yes Leitao Mario Scientific/Education Planning Committee Invited Speaker/Faculty Yes AstraZeneca Roche AstraZeneca Genentech Merck GE Healthcare Johnson&Johnson Siemens Healthcare Hisamitsu Pharmaceutical Co.Ltd. Chyugai Parmaceutical Co.Ltd. Taihou Pharmaceutical Co.Ltd. Mochida Pharmaceutical Co.Ltd. Fuji Parmaceutical Co.Ltd. Yakuruto Co.Ltd. Bayer AstraZeneca Merck Intuitive vadaq
8 Mahner Sven Scientific/Education Planning Committee Invited Speaker/Faculty Mariani Andrea Invited Speaker/Faculty Marth Christian Scientific/Education Planning Committee Invited Speaker/Faculty Poster/Oral Presenter Massuger Leon Invited Speaker/Faculty Mbatani monde Invited Speaker/Faculty McAlpine Jessica N. Invited Speaker/Faculty Yes Merck Mccluggage Glenn Invited Speaker/Faculty McNally Orla Invited Speaker/Faculty Menon Santosh Invited Speaker/Faculty Menon Usha Invited Speaker/Faculty Yes Abcodia Mileshkin Linda Invited Speaker/Faculty Yes Merck Mirza Mansoor Raza Scientific/Education Planning Committee Invited Speaker/Faculty Monk Bradley Invited Speaker/Faculty Yes Advaxis Amgen
9 Array AstraZeneca Bayer Eli Lilly Genentech
10 Insys Clovis Janssen Pharmaceuticals Merck Myriad
11 Pfizer Tesaro Roche Morphotek Mateon(formally OxiGENE)
12 Gradalis Nam Joo-Hyun Scientific/Education Planning Committee Naumann Robert Wendel Invited Speaker/Faculty Ngan Yuen Sheung Invited Speaker/Faculty Hextan O Cearbhail Roisin Invited Speaker/Faculty Obermair Andreas Scientific/Education Planning Committee Yes Invited Speaker/Faculty Odunsi Kunle Invited Speaker/Faculty Okamoto Aikou Ordi Jaume Invited Speaker/Faculty Petru Edgar Invited Speaker/Faculty Pignata Sandro Invited Speaker/Faculty Yes Plante Marie Scientific/Education Planning Committee Invited Speaker/Faculty Polterauer Stephan Invited Speaker/Faculty Pötter Richard Invited Speaker/Faculty Covidien Ethicon-endo SurgicalPerformance AstraZeneca
13 Prat Jaime Scientific/Education Planning Committee Invited Speaker/Faculty Pujade- Eric Invited Speaker/Faculty Yes Lauraine Hoffmann-La Roche AstraZeneca Pfizer Quinn Michael Scientific/Education Planning Committee Yes Invited Speaker/Faculty Roche and Tesaro Board of Directors Raspagliesi Francesco Invited Speaker/Faculty Reimer Daniel Invited Speaker/Faculty Yes AstraZeneca Reinthaller Alexander Invited Speaker/Faculty Rob Lukas Invited Speaker/Faculty Yes GlaxoSmithKline Sabbatini Paul Invited Speaker/Faculty Yes Bristol-Myers Squibb Schmeler Kathleen Seckl Michael Invited Speaker/Faculty Yes Bristol-Myers Squibb Sehouli Jalid Invited Speaker/Faculty
14 Silva Elvio Scientific/Education Planning Committee Invited Speaker/Faculty Simmonds Hannah Invited Speaker/Faculty Singh Naveena Invited Speaker/Faculty Small Bill (William),Jr Invited Speaker/Faculty Yes Zeiss Soslow Robert Invited Speaker/Faculty Yes EMD Serono, Cambridge Univ Press, Springer Publishing, NIH, DOD Tanaka Yusuke Invited Speaker/Faculty Taylor Alexandra Invited Speaker/Faculty Poster/Oral Presenter Temkin Sarah Invited Speaker/Faculty Teunissen Saskia Invited Speaker/Faculty Toral Jean Anne Touhami Omar Invited Speaker/Faculty van der Zee Ate Invited Speaker/Faculty Vandecaveye Vincent Invited Speaker/Faculty Vergote Ignace Invited Speaker/Faculty Woelber Linn Invited Speaker/Faculty Yes Poster/Oral Presenter Medac Oncology Hoffmann-La Roche Jenapharm Wright Jason Invited Speaker/Faculty
15 s' Portal osure Form Results Consulting/ Advisory Board Funded Research Royalties/ Patent Stock Options Ownership/ Equity Position Employee Other Off Label Product Use multiple investigational and approved agents including standard bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors
16 Protocol Steering Committee multiple investigational and approved agents including standard bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors multiple investigational and approved agents including standard bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors multiple investigational and approved agents including standard bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors multiple investigational and approved agents including standard bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors
17 Data Monitoring Committee multiple investigational and approved agents including standard bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors multiple investigational and approved agents including standard bevacizumab, PARP inhibitors, targeted agents, and immune checkpoint inhibitors Parp inhibitors and Combinations for research purposes Parp inhibitors and Combinations for research purposes Parp inhibitors and Combinations for research purposes Parp inhibitors and Combinations for research purposes
18 Clovis Parp inhibitors and Combinations for research purposes Parp inhibitors and Combinations for research purposes Parp inhibitors and Combinations for research purposes
19 Off-label use of hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers Off-label use of hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers Off-label use of hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers Off-label use of hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers
20 Off-label use of hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers Off-label use of hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers Off-label use of hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers Off-label use of hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers Off-label use of hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers
21 Off-label use of hormonal therapy, and investigational agents and investigational agents for rare ovarian cancers
22
23
24
25
26 We will be discussing available therapies for gynecologic malignancies and may discuss all therapies supported by the literature regardless of approval status Will discuss the use of targeted agents in the setting of clinical trials
27 avelumab, pembrolizumab, atezoluzumab avelumab, pembrolizumab, atezoluzumab avelumab, pembrolizumab, atezoluzumab avelumab, pembrolizumab, atezoluzumab I may mention the use of pembrolizumab to salvage patients who have failed everything else
28
Speakers' Portal IGCS18 CME Disclosure Form Results
Speakers' Portal IGCS18 CME Disclosure Form Results Last Name First Name Roles Relationships Company Name Abu-Rustum Nadeem Board of Directors Adams Tracey Adams Catherine Amant Frederic Arimoto Takahide
NSGO Annual Meeting 2019
Nordic Society of Gynaecological Oncology NSGO Annual Meeting 2019 Radisson Blu Scandinavia Hotel Amager Blvd. 70, 2300 Copenhagen Theme: Advances in the Management of Gynaecological Cancer Patients 27
NSGO Annual Meeting 2019
Nordic Society of Gynaecological Oncology NSGO Annual Meeting 2019 Radisson Blu Scandinavia Hotel Amager Blvd. 70, 2300 Copenhagen Theme: Advances in the Management of Gynaecological Cancer Patients 27
NSGO Annual Meeting 2019
Nordic Society of Gynaecological Oncology NSGO Annual Meeting 2019 Radisson Blu Scandinavia Hotel Amager Blvd. 70, 2300 Copenhagen Theme: Advances in the Management of Gynaecological Cancer Patients 28
Progress and Controversies in Gynecologic Oncology Conference
2013 This meeting is a prime Oncology activity. Progress and Controversies in Gynecologic Oncology Conference 15-16 February 2013 Haliç Congress Center Istanbul, Turkey www.primeoncology.org/gyncongress2013
Ovarian Cancer Conference
Memorial Sloan Kettering Cancer Center is pleased to announce: State of the Art Ovarian Cancer Conference Thursday, October 6, 2016 www.mskcc.org/ovarianconference Course Overview Advances in women s health
Critical Pathways in Breast Cancer Treatment
Critical Pathways in Breast Cancer Treatment Faculty Jenny C Chang, MD Paul E Goss, MD, PhD Kathy D Miller, MD Lawrence N Shulman, MD Dennis J Slamon, MD, PhD Andrew Tutt, MB ChB, PhD Editor Neil Love,
Oncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3
290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3 Presentation Number: 290O Lecture Time: 11:18-11:33 Speakers: Peter
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
The new england journal of medicine Original Article Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer M.R. Mirza, B.J. Monk, J. Herrstedt, A.M. Oza, S. Mahner, A. Redondo, M. Fabbro,
Poster Presented at the 2014 American College of Rheumatology Annual Meeting
Poster Presented at the 2014 American College of Rheumatology Annual Meeting Anne Winkler 1 James Mossell 2 Edmund MacLaughlin 3 Drew Johnson 4 J. Timothy Harrington 5 1 Winkler Medical Practice LLC, Springfield,
ESMO Symposium on Immuno-Oncology Programme book
IMMUNO-ONCOLOGY SYMPOSIUM ESMO Symposium on Immuno-Oncology Programme book Advances in cancer immunotherapy; From vaccines to antibodies and cell therapies Geneva Switzerland 15-16 NOVEMBER 2013 esmo.org
University of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
OVARIAN. CANCER Optimal Therapy. Update ADVANCED. 12 th International Symposium. Valencia, 22 nd February
Organized by Valencia, 22 nd February 2019 12 th International Symposium ADVANCED OVARIAN CANCER Optimal Therapy. Update DIRECTORS Andrés Poveda Initia Oncology, Hospital Quirónsalud, Valencia, Spain Jan
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES All individuals able to influence or control content of any CME certified activity that will be presented were required to complete
Organizational, or Other Financial Benefit None None None None None None. None None None None None None
Comprehensive Relationships With Industry and Other Entities AHA/ACC 2017 Update of ST-Elevation Myocardial Infarction and Non ST-Elevation Myocardial Infarction Measures Committee Jneid Hani, Chair Baylor
Promius Pharma, a subsidiary of Dr. Reddy s Laboratories, Princeton, NJ; 2 Vedanta Research, Chapel Hill, NC; 3
Triptan Use and Discontinuation Among a Population Sample of Persons with Migraine: Results from Migraine in America Symptoms and Treatment (MAST) Study Aftab Alam, MBBS, MS, MBA 1 ; Sagar Munjal, MD 1
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES All individuals able to influence or control content of any CME certified activity that will be presented were required to complete
Industry Supported Symposium Steering improved outcomes in non-driver mutation lung cancer: progress and challenges
IASLC 19 th World Conference on Lung Cancer Industry Supported Symposium Steering improved outcomes in non-driver mutation lung cancer: progress and challenges Chaired by Mark A. Socinski With Keith Kerr,
Do the Right Thing: Good Clinical Practice for Clinical Research
Do the Right Thing: Good Clinical Practice for Clinical Research Andrew A. Nierenberg, MD Director, Bipolar Clinic and Research Program, Director, Training and Education, MGH Research Institute Massachusetts
Faculty. Course Directors. Liza Blumenfeld, MA, CCC-SLP, BCS-S UC San Diego Health - Speech-Language Pathologist
Faculty Course Directors Liza Blumenfeld, MA, CCC-SLP, BCS-S UC San Diego Health - Speech-Language Pathologist Non-financial Disclosure: Developer of Swallow RehApp Joseph Califano, MD UC San Diego Health
Gynecologic Oncology
Gynecologic Oncology 136 (2015) 37 42 Contents lists available at ScienceDirect Gynecologic Oncology journa l homepage: www. elsevier. com/ locate/ ygyno Progression-free survival by local investigator
First-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC)
Key ASCO Presentations Issue 7, 2010 First-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC) For more visit ResearchToPractice.com/5MJCMT2010
Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML
Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML CME INFORMATION OVERVIEW OF ACTIVITY Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) account for approximately
TNF Inhibitors: Lessons From Immunogenicity
TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:
CME Information. ResearchToPractice.com/AUABladder17 1
What Urologists Want to Know: Addressing Current Questions and Controversies Regarding the Role of Immune Checkpoint Inhibitors in the Management of Bladder Cancer CME Information TARGET AUDIENCE This
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
Visiting Professors. Clinical Investigators Review Key Publications and Current Cases in Gynecologic Oncology
Visiting Professors Clinical Investigators Review Key Publications and Current Cases in Gynecologic Oncology C M E I N F O R M A T I O N TARGET AUDIENCE This activity is intended for gynecologic and medical
Key ASCO Presentations Issue 2, Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases
Key ASCO Presentations Issue 2, 2010 Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF ACTIVITY Each year,
th International Charité Mayo Conference
PREPUBLICATION SCIENTIFIC PROGRAM v 10 Global Perspectives and Future Directions in Women s Cancer April 3 6, 2019 Berlin th International Charité Mayo Conference CALL FOR ABSTRACTS www.charite-mayo.de
ToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC)
ToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC) For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians
Giancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis
COMPARISON OF EARLY AND DELAYED ORAL LAQUINIMOD IN PATIENTS WITH RELAPSING- REMITTING MULTIPLE SCLEROSIS: EFFECTS ON DISABILITY PROGRESSION AT 36 MONTHS IN THE ALLEGRO TRIAL Giancarlo Comi, M.D. On Behalf
SUPPLEMENTARY DATA. Telediab Study Group :
Telediab Study Group : Guillaume Charpentier, MD, Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France Centre d Études et de Recherches pour l Intensification du Traitement du Diabète
New Prognostic Markers in Acute Myeloid Leukemia (AML)
New Prognostic Markers in Acute Myeloid Leukemia (AML) For more visit ResearchToPractice.com/5MJCMDSAML CME INFORMATION OVERVIEW OF ACTIVITY Acute myeloid leukemia (AML) and the myelodysplastic syndromes
KEYNOTE PRESENTATION. Edward A Stadtmauer, MD and Patricia Mangan, MSN, CRNP
AGENDA Access Pre/Post Tests and Presentations: PennMedicine.org/Abramson/BloodCME Password: Blood2018 (case sensitive) For Free Wi-Fi use HHonors Promotion Code: phlph2218 7:30 am Registration and Continental
Abstract Background: Methods: Results: Conclusion:
1055 Two-Year Safety of, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Psoriasis: Results From a Phase 3, Randomized, Controlled Trial () Kim A. Papp, MD 1 ; Kristian Reich,
Key ASCO Presentations Issue 4, Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM)
Key ASCO Presentations Issue 4, 2010 Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM) For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
4892 Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis ( Phase IV Study) Bruce Strober, MD 1 ; Jerry Bagel, MD 2 ; Mark Lebwohl, MD 3 ; Linda Stein Gold, MD 4 ; J. Mark Jackson,
History of ASGO and International Collaboration. Kurume University, Kurume, Japan Toshiharu Kamura, MD, PhD.
History of ASGO and International Collaboration Kurume University, Kurume, Japan Toshiharu Kamura, MD, PhD. IGCS 2002 Seoul, Korea President Prof. Jung-Eun Mok In 1997, the 6 th IGCS was held in Japan,
Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
Editorial Team Conflict of Interest Statements
Editorial Team Conflict of Interest Statements Editor in Chief David Dodick Advisory board/consultant: Allergan, Amgen, Alder, Arteaus, Pfizer, Colucid, Merck, ENeura, NuPathe, Eli Lilly, Autonomic Technologies,
VULVAR CANCER QUALITY INDICATORS
VULVAR CANCER QUALITY INDICATORS www.esgo.org The European Society of Gynaecological Oncology (ESGO) has developed a list of quality indicators for vulvar surgery that can be used to audit and improve
Patient 1: 31-Year-Old Female. Fingolimod treatment
Cell Counts (10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Lymphocyte Pharmacodynamics and Safety of Use in Patients Previously
SPECIAL EDITION Issue 1, 2011
SPECIAL EDITION Issue 1, 2011 Studies in Advanced NSCLC of Maintenance Pemetrexed and Erlotinib and of BIBW 2992 or MetMAb Targeted Therapy for Acquired Resistance to Erlotinib and Gefitinib For more visit
Real-Life Decisions. Proceedings from a Case-Based Symposium on the Management of Early and Advanced Breast Cancer
Real-Life Decisions Proceedings from a Case-Based Symposium on the Management of Early and Advanced Breast Cancer Featuring Faculty Perspectives on New Data Sets Presented at the 33 rd Annual San Antonio
Healthcare Professional Information & Patient Information Leaflet (PL)
New concept for the SmPC/ Healthcare Professional Information & Patient Information Leaflet (PL) Fiona Reekie Director Global Regulatory Affairs Johnson & Johnson Pharmaceuticals Group Disclaimer The views
Key ASH Presentations Issue 2, Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL)
Key ASH Presentations Issue 2, 2011 Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL) For more visit ResearchToPractice.com/5MJCASH2011 CME INFORMATION OVERVIEW OF ACTIVITY The annual
NAME CTS AFFILIATION DISCLOSURE UPDATED
NAME CTS AFFILIATION DISCLOSURE UPDATED Darcy Marciniuk (Chair) and Canadian and Canadian COPD Alliance Consultant Fee, Speaker s Bureau, Advisory Committee: AstraZeneca, Boehringer-Ingelheim, Canadian
C-SSRS/KIT version includes. C-SSRS Scoring/ Administration instructions (13pgs)
This is a Sample version of the Columbia-Suicide Severity Rating Scale (C-SSRS) KIT The full version of watermark.. the C-SSRS/KIT comes without sample The full complete C-SSRS/KIT version includes C -SSRS
Bevacizumab (Bev) with Chemotherapy, Followed by Bev, in the Treatment of Newly Diagnosed and Platinum- Sensitive Recurrent Ovarian Cancer
SPECIAL EDITION Issue 1, 2011 Bevacizumab (Bev) with Chemotherapy, Followed by Bev, in the Treatment of Newly Diagnosed and Platinum- Sensitive Recurrent Ovarian Cancer For more visit ResearchToPractice.com/5MJCASCO2011
Cancer Researchers Report Longer Survival Rates With Immunotherapy
http://nyti.ms/1jlz74z HEALTH NYT NOW Cancer Researchers Report Longer Survival Rates With Immunotherapy By ANDREW POLLACK JUNE 2, 2014 CHICAGO Drugs that unleash the body s immune system to combat tumors
Targeted Agent and Profiling Utilization Registry
Targeted Agent and Profiling Utilization Registry Richard L. Schilsky, MD, FACP, FASCO Senior Vice President and Chief Medical Officer American Society of Clinical Oncology Disclosure Information Richard
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
Second Opinion An Interactive Case-Based Discussion on the Management of Early and Advanced Breast Cancer
Second Opinion An Interactive Case-Based Discussion on the Management of Early and Advanced Breast Cancer Proceedings from a CME Satellite Symposium at the 30 th Annual San Antonio Breast Cancer Symposium
CME Information. ResearchToPractice.com/ThoracicCancers17/Nontargeted 1
CONSENSUS OR CONTROVERSY: Clinical Investigators Provide Perspectives on the Treatment of Metastatic Non-Small Cell Lung Cancer in Patients without Targetable Tumor Mutations CME Information TARGET AUDIENCE
Save Up To $125 with Early Bird Rates through August 21!
Save Up To $125 with Early Bird Rates through August 21! Experience BIG IDEAS, KEY STRATEGIES, and PRACTICAL TAKEAWAYS that will help transform how you deliver patient care! REGISTER TODAY! accc-cancer.org/oncologyconference
NEW AGENTS AND STRATEGIES IN THE MANAGEMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
NEW AGENTS AND STRATEGIES IN THE MANAGEMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA CME Information TARGET AUDIENCE This activity is intended for medical oncologists, hematologists and other healthcare providers
Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer
Saturday, October 27, 2018 7:00 AM - 3:45 PM Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer Program Director John V.
BGCS Thursday 5 th July. Time Session Location 7:30-9:30 Registration. Cervical Cancer Control in the UK now and in the future
Thursday 5 th July 7:30-9:30 Registration 8:35-9:20 Dynamic Fluorescent Imaging In Gynaecological Oncology Surgery Meeting sponsored by Stryker Rutherford 8:35-9:20 Cervical Cancer Control in the UK now
Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study
Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study Michael J Koren 1, Robert P Giugliano 2, Frederick Raal 3, David
Journal of the American College of Cardiology
Advertisement Journal of the American College of Cardiology Volume 72, Issue 3, July 2018 DOI: 10.1016/j.jacc.2018.04.063 PDF Article Download Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory
Kenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
Lung Cancer in Older Adults.. Appropriate treatment?
Lung Cancer in Older Adults.. Appropriate treatment? Faculty Disclosure X No, nothing to disclose Yes, please specify: Dr Christopher Steer Border Medical Oncology Albury-Wodonga Inaugural Chair Geriatric
THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER. HLC143A June Usha Nagavarapu Project Analyst ISBN: X
THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER HLC143A June 2013 Usha Nagavarapu Project Analyst ISBN: 1-56965-431-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
DLQI (ESTEEM
192 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pruritus and DLQI Correlations at Week 16 (ESTEEM 1 and 2) Steven R. Feldman, MD, PhD 1 ; Diamant
NCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17
OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay
Abbott Nutrition 1030 AbbVie 301 AbbVie 907 About the Nurse 207 Academy of Medical-Surgical Nurses 144 Academy of Oncology Nurse & Patient Navigators
Exhibitor Name Booth Number Abbott Nutrition 1030 AbbVie 301 AbbVie 907 About the Nurse 207 Academy of Medical-Surgical Nurses 144 Academy of Oncology Nurse & Patient Navigators 358 Accredo 947 Adako 276
RARE TUMOR Working Group. Thursday, May 30, 2013, 3:30 p.m. 5:30 pm. Huron Room, Doubletree Hotel, Chicago MINUTES
GCIG RARE TUMOR Working Group Thursday, May 30, 2013, 3:30 p.m. 5:30 pm Huron Room, Doubletree Hotel, Chicago MINUTES I.Ray-Coquard (Chair), J.Ledermann (co-chair) Attendees: A. Jhingran (RTOG), C.Chu
Histology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and
June 4, Via Electronic Transmission
June 4, 2008 Via Electronic Transmission Dr. Drew Gilpin Faust President Harvard University Massachusetts Hall Cambridge, MA 02138 Dr. Peter L. Slavin President Massachusetts General Hospital (Partners
Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
Wednesday, February 24 th, 2016
List of Faculty: Nadeem R. Abu-Rustum, Giovanni Aletti, Istituto Europeo di Oncologia. Milan, Italy Natalia Carballo, Carlos Centeno, Clínica Universidad de Navarra. Pamplona, Spain David Cibula, General
Oncology Market Forecast To 2013
Oncology Market Forecast To 2013 How do you uncover the threats and opportunities that your oncology drug will face this year, next year and each year after that? Our new report answers your questions
IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC Vassiliki A. Papadimitrakopoulou, 1 Manuel Cobo, 2 Rodolfo Bordoni, 3 Pascale
INCIDENCE OF ADVERSE EVENTS COMPARING ABDOMINAL VS. MINIMALLY INVASIVE RADICAL HYSTERECTOMY IN PATIENTS WITH EARLY-STAGE CERVICAL CANCER: LACC TRIAL
INCIDENCE OF ADVERSE EVENTS COMPARING ABDOMINAL VS. MINIMALLY INVASIVE RADICAL HYSTERECTOMY IN PATIENTS WITH EARLY-STAGE CERVICAL CANCER: LACC TRIAL Andreas Obermair, Rebecca Asher, Michael Frumovitz,
THE NEW BIOLOGY OF NON-SMALL CELL LUNG CANCER
THE NEW BIOLOGY OF NON-SMALL CELL LUNG CANCER CME Information TARGET AUDIENCE This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.
Gastric Cancer Care: From evidence to practice
ESMO Asia 2017 Industry Satellite Symposium Gastric Cancer Care: From evidence to practice Chaired by Ian Chau With Jae-Ho Cheong, Eva Segelov and Kohei Shitara Friday 17th November, 12:45-14:15, Level
Conversations with Urologic Oncology Investigators Bridging the Gap between Research and Patient Care
PCU T HINK TA NK ISSUE 1 Conversations with Urologic Oncology Investigators Bridging the Gap between Research and Patient Care F A C U L T Y Robert Dreicer, MD, MS Stephen J Freedland, MD Philip Kantoff,
Fifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
The Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study
2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers May 27 30, 2015 Indianapolis, IN The Effects of Daclizumab High Yield Process () on Patient Centered Functional Outcomes: Results From
US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY
AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY Maximilian J. Hochmair, 1 Alessandro Morabito, 2 Desiree Hao, 3 Cheng-Ta Yang, 4 Ross A.
Welcome and PRO Consortium Update
Welcome and PRO Consortium Update Stephen Joel Coons, PhD Executive Director, PRO Consortium FIFTH ANNUAL PATIENT-REPORTED OUTCOME (PRO) CONSORTIUM WORKSHOP April 29-30, 2014 Silver Spring, MD Co-sponsored
S1207 Trial of Adjuvant Endocrine Therapy with or without Everolimus for High-Risk, Hormone Receptor-Positive, HER2-Negative Breast Cancer
POST-SABCS Issue 1, 2013 S1207 Trial of Adjuvant Endocrine Therapy with or without Everolimus for High-Risk, Hormone Receptor-Positive, HER2-Negative Breast Cancer For more visit ResearchToPractice.com/5MJCSABCS2013
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
A Prospective Outcomes Analysis of Palliative Procedures Performed for Malignant Intestinal Obstruction Due to Recurrent Ovarian Cancer
The Oncologist Gynecologic Oncology A Prospective Outcomes Analysis of Palliative Procedures Performed for Malignant Intestinal Obstruction Due to Recurrent Ovarian Cancer DENNIS S. CHI, a REBECCA PHAËTON,
Finding the Positives in Triple- Negative Breast Cancer: A Three- Part Live CME Webcast Series
Finding the Positives in Triple- Negative Breast Cancer: A Three- Part Live CME Webcast Series Seminar I: Wednesday, March 3, 2010, 8:00 PM - 9:00 PM EST Neil Love, MD Editor, Breast Cancer Update Audio
Saturday, November 4, 2017
Program as of 3.9.17. please use only the Interactive program for the most updated version. Saturday, November 4, 2017 ORAL COMMUNICATION: BEST ORAL PRESENTATIONS 01 09:30-10:30 HALL A Chair: David Cibula
Professor Caroline Sabin
Professor Caroline Sabin in partnership with Royal Free & University College Medical School London, UK COMPETING INTEREST OF FINANCIAL VALUE > 1,000 Statement Over the past five years, Caroline Sabin has
New Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
Immune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy
Immune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy Philip Mease MD Director, Rheumatology Clinical Research, Swedish- Providence St. Joseph Health Clinical Professor, University of Washington
CLINICAL GUIDELINES COMMITTEE September 9-10, 2014 DISCLOSURE OF INTERESTS
CLINICAL GUIDELINES COMMITTEE September 9-10, 2014 DISCLOSURE OF INTERESTS NAME Financial INTERESTS Non-Financial Thomas Denberg, MD, PhD, FACP, Chair Michael J. Barry, MD, MACP Indicate Employment: Carilion
Depressive and anxiety symptoms in academic physicians (R. Lam)
R3 Research Presentation Depressive and anxiety symptoms in academic physicians (R. Lam) St.-Antoine, Friday, Oct. 26, 2012 (3:45 pm-5:15 pm) Depressive and Anxiety Symptoms in Academic Physicians Raymond